Literature DB >> 22626986

From genes to cognition in tuberous sclerosis: implications for mTOR inhibitor-based treatment approaches.

Dan Ehninger1.   

Abstract

Tuberous sclerosis (TSC) is a neurocutaneous disorder with an autosomal-dominant pattern of inheritance and is caused by heterozygous mutations in the TSC1 or TSC2 gene. Neuropsychiatric conditions, including intellectual disability, autism and epilepsy, are highly prevalent in TSC populations. Here, I review recent findings that shed light on some of the neurobiological mechanisms that may contribute to the pathogenesis of TSC-associated neuropsychiatric impairments. Emerging intervention studies in animal models show striking effects of mTORC1 inhibitors on TSC-related CNS manifestations. Translational studies that assess the effects of mTORC1 inhibitors on neuropsychiatric phenotypes in human TSC individuals are underway. This article is part of the Special Issue entitled 'Neurodevelopmental Disorders'.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22626986     DOI: 10.1016/j.neuropharm.2012.05.015

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  25 in total

Review 1.  Using genetic findings in autism for the development of new pharmaceutical compounds.

Authors:  Jacob A S Vorstman; Will Spooren; Antonio M Persico; David A Collier; Stefan Aigner; Ravi Jagasia; Jeffrey C Glennon; Jan K Buitelaar
Journal:  Psychopharmacology (Berl)       Date:  2013-11-30       Impact factor: 4.530

2.  Papillary thyroid carcinoma in a boy with familial tuberous sclerosis complex attributable to a TSC2 deletion-a case report.

Authors:  M Flader; P Kurzawa; J Maldyk; J Sygut; J Harasymczuk; A Kropinska; D Handkiewicz-Junak; B Jarzab; K Kotulska; M Niedziela
Journal:  Curr Oncol       Date:  2017-10-25       Impact factor: 3.677

Review 3.  Neurobiology of autism gene products: towards pathogenesis and drug targets.

Authors:  Kristel T E Kleijer; Michael J Schmeisser; Dilja D Krueger; Tobias M Boeckers; Peter Scheiffele; Thomas Bourgeron; Nils Brose; J Peter H Burbach
Journal:  Psychopharmacology (Berl)       Date:  2014-01-14       Impact factor: 4.530

4.  A lipid off-switch for mTORC1.

Authors:  Alexander Wallroth; Volker Haucke
Journal:  Mol Cell Oncol       Date:  2017-08-02

5.  Normalizing translation through 4E-BP prevents mTOR-driven cortical mislamination and ameliorates aberrant neuron integration.

Authors:  Tiffany V Lin; Lawrence Hsieh; Tomoki Kimura; Taylor J Malone; Angélique Bordey
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-19       Impact factor: 11.205

6.  Convergence Science Arrives: How Does It Relate to Psychiatry?

Authors:  Harris A Eyre; Helen Lavretsky; Malcolm Forbes; Cyrus Raji; Gary Small; Patrick McGorry; Bernhard T Baune; Charles Reynolds
Journal:  Acad Psychiatry       Date:  2016-03-10

7.  Common EIF4E variants modulate risk for autism spectrum disorders in the high-functioning range.

Authors:  Regina Waltes; Johannes Gfesser; Denise Haslinger; Katja Schneider-Momm; Monica Biscaldi; Anette Voran; Christine M Freitag; Andreas G Chiocchetti
Journal:  J Neural Transm (Vienna)       Date:  2014-05-13       Impact factor: 3.575

8.  Forebrain depletion of Rheb GTPase elicits spatial memory deficits in mice.

Authors:  Neelam Shahani; Wen-Chin Huang; Megan Varnum; Damon T Page; Srinivasa Subramaniam
Journal:  Neurobiol Aging       Date:  2016-11-21       Impact factor: 4.673

9.  Rapamycin improves sociability in the BTBR T(+)Itpr3(tf)/J mouse model of autism spectrum disorders.

Authors:  Jessica A Burket; Andrew D Benson; Amy H Tang; Stephen I Deutsch
Journal:  Brain Res Bull       Date:  2013-12-01       Impact factor: 4.077

10.  Genetic reduction of mammalian target of rapamycin ameliorates Alzheimer's disease-like cognitive and pathological deficits by restoring hippocampal gene expression signature.

Authors:  Antonella Caccamo; Vito De Pinto; Angela Messina; Caterina Branca; Salvatore Oddo
Journal:  J Neurosci       Date:  2014-06-04       Impact factor: 6.167

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.